Regeneron Pharmaceuticals

Yahoo Finance • 10 days ago

Stocks Fall Slightly in Thin Holiday Trade

The S&P 500 Index ($SPX) (SPY) on Tuesday closed down -0.14%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.20%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.25%.  March E-mini S&P futures (ESH26) fell -0.14%, and M... Full story

Yahoo Finance • 10 days ago

Stocks Slip as Bond Yields Rise

The S&P 500 Index ($SPX) (SPY) today is down -0.12%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.25%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.11%.  March E-mini S&P futures (ESH26) are down -0.11%, and March E-mini N... Full story

Yahoo Finance • 18 days ago

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and im... Full story

Yahoo Finance • 18 days ago

Communiqué de presse : Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique

Le Dupixent de Sanofi et Regeneron approuvé au Japon pour les enfants de 6 à 11 ans atteints d’asthme bronchique Approbation basée sur le programme mondial de phase 3 chez les enfants démontrant que le Dupixent a considérablement réduit l... Full story

Yahoo Finance • 18 days ago

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupixent is the first and only biologic med... Full story

Yahoo Finance • 18 days ago

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Regeneron Pharmaceuticals, Inc. TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 20... Full story

Yahoo Finance • 21 days ago

Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S.

[Chemist developing new medicine in laboratory] Luis Alvarez Alvotech (ALVO [https://seekingalpha.com/symbol/ALVO]) and Teva Pharmaceuticals (TEVA [https://seekingalpha.com/symbol/TEVA]) have reached a settlement and license agreement wit... Full story

Yahoo Finance • 23 days ago

Merck cholesterol, cancer therapies to receive national priority vouchers - report

[FDA headquarters in Washington DC.] JHVEPhoto Merck's oral PCSK inhibitor for cholesterol, enlicitide, and its cancer antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) will become the next two treatments to gain accelerated revie... Full story

Yahoo Finance • 29 days ago

Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight

ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling 'unprecedented.' Major pharmaceutical developers such as Johnson & Johnson, Arcellx, Gilead, Bris... Full story

Yahoo Finance • 30 days ago

China Leads Therapeutic Access with 74 Approved Immuno-Oncology Agents

Dublin, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Immuno-oncology (2025)" has been added to ResearchAndMarkets.com's offering. The latest report delves into the dynamic field of immuno-oncology, shedding light on c... Full story

Yahoo Finance • last month

​Sanofi (SNY) Completes the Acquisition of Vicebio

​Sanofi (NASDAQ:SNY) is one of the Cheap NASDAQ Stocks to Buy Now. On December 4, Sanofi (NASDAQ:SNY) announced the completion of the Vicebio acquisition. Vicebio is a clinical-stage biotechnology company focused on developing transformati... Full story

Yahoo Finance • last month

Kymera jumps on early-stage data for eczema candidate KT-621

[a girl scratches the skin on the elbow of her arm, redness is atopic dermatitis, the girl s face is not visible] Evgeniia Gordeeva * Kymera Therapeutics (KYMR [https://seekingalpha.com/symbol/KYMR]) is up ~51% in Monday trading after r... Full story

Yahoo Finance • last month

Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term.Regeneron’s (REGN) Recovery and Dupixent Strength Support BMO’s Outperform Rating On December 4, BMO Capital analyst Evan Seigerman... Full story

Yahoo Finance • last month

Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?

Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema. Continue Reading... Full story

Yahoo Finance • last month

Regeneron Reports Promising Phase 1/2 Data Of Lynozyfic In Newly Diagnosed Multiple Myeloma

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic (linvoseltamab) in adults with newly diagnosed multiple myeloma (NDMM), both transplant-eligible and t... Full story

Yahoo Finance • last month

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy, with VGPR+ (very good partial response or better) of ≥70% despite limited follow-up; evidence shows that these responses are expected to deepen over t... Full story

Yahoo Finance • last month

Notable healthcare headlines for the week: UnitedHealth, Eli Lilly, and Bristol Myers in focus

Wall Street's major averages closed in the green on Friday, as traders assessed fresh inflation data in hopes of gauging the Federal Reserve's monetary policy. The benchmark S&P 500 closed +0.2%, while the Nasdaq Composite ended +0.3%, an... Full story

Yahoo Finance • last month

Is Alnylam Pharmaceuticals a Millionaire Maker?

Key Points Alnylam has been a big winner for investors since its IPO in 2004. The drugmaker's future looks promising. Whether or not Alnylam is a millionaire maker, the stock should be able to generate exceptional long-term returns.10 sto... Full story

Yahoo Finance • last month

Regeneron downgraded at Morgan Stanley on valuation level

[Wall Street New York stock exchange stock market] alexsl Morgan Stanley has downgraded Regeneron Pharmaceuticals (REGN [https://seekingalpha.com/symbol/REGN]) to equal-weight from overweight saying that the stock is fairly valued. The b... Full story

Yahoo Finance • last month

Oracle initiated, Uber upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Arete upgraded Uber (UBER) to Buy from... Full story